Clinical Commander

Back to dossier
cardio.cardiogenic-shock.eosinophilic-myocarditis.v1PRODUCTION
cardio.cardiogenic-shock.eosinophilic-myocarditis.v1

Cardiogenic shock — Eosinophilic myocarditis (hypersensitivity / parasitic / HES / EGPA)

cardiologyacuteadult
Hard-required inputs
0 / 14
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm eosinophilic myocarditis with cardiogenic shock — peripheral eosinophilia >1500/µL + LV dysfunction + shock physiology + ESC 2013 myocarditis criteria; identify etiology (drug-induced/parasitic/HES/EGPA/idiopathic)

Inputs
2
Actions
0
Advance rule
Set
Advance when

Eosinophilic myocarditis confirmed + CS overlay documented + etiology workup launched

Patient inputs (15)

Lake Louise criteria + LGE (subendocardial/endocardial-predominant pattern in eosinophilic myocarditis vs subepicardial in viral); helps avoid biopsy in some cases

GOLD STANDARD — eosinophilic infiltrate + necrosis + endomyocardial fibrosis; differentiates from giant-cell, lymphocytic; determines etiology subtype

Age affects steroid risk profile + comorbidity burden; HES presents in middle age (30–50); DRESS can occur at any age; EGPA peaks 40–60

End-organ damage marker; renal function gates DOAC dosing for mural thrombus and EGPA renal involvement screen

Identify offending drug (antibiotics, antipsychotics, anticonvulsants, allopurinol) — discontinuation is a critical treatment step

Absolute eosinophil count >1500/µL is the diagnostic anchor; >5000 strongly suggests HES; trend monitors steroid response

Marker of myocardial injury; trend with steroid response

HF severity marker; trend with response

MANDATORY before steroid initiation — strongyloides serology (steroids cause hyperinfection syndrome → fatal); also toxocara, schistosoma, trichinella per exposure history

ANCA positivity (typically MPO-ANCA) supports EGPA diagnosis (Churg-Strauss); changes treatment to add cyclophosphamide/rituximab

Wall thickening, LV dysfunction, mural thrombus from endocardial damage, pericardial effusion screen

T-wave inversions, PR depression (pericardial involvement), heart block (eosinophilic infiltrate of conduction system); rule out STEMI

SCAI 2022 staging baseline; eosinophilic myocarditis CS often responds rapidly to steroids

SCAI 2022 staging + response to therapy; steroid response often shows rapid lactate clearance (within 24–48 h)

Identifies clonal HES treated with IMATINIB rather than just steroids; dramatic response to imatinib if positive (Cools NEJM 2003)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningdrug_induced_dress_overlay_with_multi_organ_failure
    DRESS syndrome (fever + rash + lymphadenopathy + eosinophilia + multi-organ failure including hepatitis + nephritis) with cardiac involvement — DISCONTINUE offending drug + steroids; high mortality if not recognized
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsteroid_refractory_progression_to_rcm
    No clinical response to steroids at 72 h + rising troponin + persistent eosinophilia + echo showing endocardial fibrosis pattern → progression to restrictive cardiomyopathy (Loeffler endocarditis); add second-line therapy + advanced HF evaluation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningrefractory_ventricular_arrhythmia_from_conduction_infiltrate
    Recurrent VT/VF or progressive heart block from eosinophilic infiltration of conduction system despite steroid therapy → temporary pacing → permanent pacemaker if persistent; ICD evaluation for VT/VF
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverehes_with_fip1l1_pdgfra_discovered
    FIP1L1-PDGFRA mutation positive (clonal hypereosinophilic syndrome) — add IMATINIB 100–400 mg/d immediately; dramatic response expected within days; can be sole therapy or steroid-sparing
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereparasite_positive_workup_results
    Parasite serology or stool O&P positive (toxocara, schistosoma, trichinella, strongyloides) — initiate organism-specific antiparasitic; coordinate with steroids carefully (treat parasite first or simultaneously to prevent inflammatory flare)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Eosinophilic myocarditis CS — STEROIDS as foundation (after parasite exclusion); etiology-specific add-ons (imatinib for FIP1L1-PDGFRA+ HES; mepolizumab for refractory HES; cyclophosphamide/rituximab for EGPA; antiparasitic for parasitic; drug withdrawal for hypersensitivity); standard CS support per parent
axis: eosinophilic_myocarditis_cs_phenotype
Selected axis "Eosinophilic myocarditis CS — STEROIDS as foundation (after parasite exclusion); etiology-specific add-ons (imatinib for FIP1L1-PDGFRA+ HES; mepolizumab for refractory HES; cyclophosphamide/rituximab for EGPA; antiparasitic for parasitic; drug withdrawal for hypersensitivity); standard CS support per parent" by default fallback (first axis)
  • methylprednisolone
    first line
    glucocorticoid_iv_pulse
    1 g IV daily × 3–5 d (pulse therapy) • IV • daily × 3–5 d
    triggers: eosinophilic_myocarditis_with_shock, parasite_workup_negative_or_pending_with_clinical_imperative
    AHA 2020 myocarditis statement + Brambatti JACC 2017 — pulse steroids are foundation of therapy; dramatic response in 24–72 h in most cases; MUST exclude strongyloides hyperinfection risk first
    rxcui 6902
  • prednisone
    first line
    glucocorticoid_oral
    1 mg/kg/d (max 80 mg/d) PO • PO • daily, taper over 6–12 mo
    triggers: post_pulse_methylprednisolone_transition, maintenance_phase
    AHA 2020 myocarditis statement — slow taper over 6–12 mo to prevent recurrence; recurrence rate ~25% with rapid taper
    rxcui 8640
  • imatinib
    comorbidity specific
    tyrosine_kinase_inhibitor_pdgfra
    100–400 mg PO daily • PO • daily
    triggers: hypereosinophilic_syndrome_with_fip1l1_pdgfra_positive
    Cools NEJM 2003 — dramatic response in FIP1L1-PDGFRA+ clonal HES; can be sole therapy or steroid-sparing; check echo + EF before to monitor for cardiotoxicity
    rxcui 282388
  • mepolizumab
    comorbidity specific
    anti_il5_monoclonal_antibody
    300 mg SC q4wk • SC • q4wk
    triggers: steroid_refractory_hypereosinophilic_syndrome, egpa_steroid_sparing
    Roufosse NEJM 2008 — anti-IL-5 antibody; steroid-sparing in HES + EGPA; FDA approved for HES (2020) and EGPA (2017)
    rxcui 1720597
  • cyclophosphamide
    comorbidity specific
    alkylating_immunosuppressant
    0.5–1 g/m² IV monthly × 3–6 mo • IV • monthly
    triggers: egpa_with_severe_organ_involvement_including_myocarditis, severe_systemic_vasculitis
    EULAR 2016 EGPA + severe organ involvement — induction therapy; combine with steroids; transition to maintenance with rituximab/azathioprine/mepolizumab
    rxcui 3002
  • rituximab
    comorbidity specific
    anti_cd20_monoclonal_antibody
    375 mg/m² IV weekly × 4 (or 1 g IV × 2) • IV • per induction protocol
    triggers: egpa_alternative_to_cyclophosphamide, egpa_relapsing_disease
    EULAR 2016 EGPA — alternative or maintenance after cyclophosphamide induction; useful if fertility preservation concern
    rxcui 121191
  • albendazole
    comorbidity specific
    antiparasitic_benzimidazole
    400 mg PO BID × 5–14 d (varies by organism) • PO • BID
    triggers: parasitic_eosinophilic_myocarditis_toxocariasis_or_trichinellosis_or_strongyloidiasis
    WHO antiparasitic guidelines; combine with steroids cautiously after parasite treatment initiated to prevent inflammation flare
    rxcui 430
  • ivermectin
    comorbidity specific
    antiparasitic_avermectin
    200 µg/kg PO daily × 1–2 d (repeat in 2 wks for strongyloides) • PO • daily
    triggers: strongyloidiasis_confirmed_or_suspected_high_risk_pre_steroids
    CDC strongyloidiasis treatment — empiric in high-risk patients before steroids; prevents fatal hyperinfection syndrome
    rxcui 6069
  • norepinephrine
    first line
    vasopressor_alpha
    0.05–0.5 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: eosinophilic_myocarditis_with_cs_sbp_lt_90
    SOAP-II PMID 20200382 — NE first-line in CS; standard CS support while steroids take effect (24–72 h)
    rxcui 7512
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg daily; INR target 2–3 • PO • daily × 3 mo
    triggers: ef_lt_35_with_endocardial_involvement, lv_thrombus_on_echo, loeffler_endocarditis_pattern
    AHA 2022 Class IIa for LV thrombus; eosinophilic myocarditis carries elevated thrombus risk from endocardial damage (Loeffler endocarditis pattern)
    rxcui 11289
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg BID (or 2.5 mg BID per dose-reduction criteria) • PO • BID × 3 mo for mural thrombus prophylaxis
    triggers: warfarin_intolerant_or_inr_compliance_concern, endocardial_involvement_with_severe_lv_dysfunction
    Off-label-but-rational DOAC alternative for LV thrombus prophylaxis
    rxcui 1364430

outpatient playbook — drug actions (4)

  1. 1. continue prednisone taper over 6–12 mo
    taper per schedule • PO • daily
    trigger: Maintenance phase
    AHA 2020 slow taper to prevent recurrence
  2. 2. continue or de-escalate etiology-specific therapy
    per response • per protocol • per protocol
    trigger: Long-term remission
    HES → maintain imatinib/mepolizumab; EGPA → maintenance with rituximab/azathioprine/mepolizumab; parasitic → completed course
  3. 3. discontinue warfarin / apixaban at 3 mo if EF recovered + endocardial damage stable
    taper / stop • PO • n/a
    trigger: Normalized echo + CMR at 3 mo
    Mural thrombus risk resolves with disease control
  4. 4. continue HFrEF GDMT if persistent LV dysfunction
    lisinopril + carvedilol + MRA + SGLT2i per AHA 2022 • PO • as scheduled
    trigger: Persistent EF<40
    AHA 2022 HF Class I

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Peripheral absolute eosinophil count >1500/µL (often >5000) + new severe LV dysfunction + shock physiology — eosinophilic myocarditis until proven otherwise; DRESS syndrome (fever + rash + lymphadenopathy + eosinophilia + multi-organ involvement) + new cardiac dysfunction → drug-induced hypersensitivity eosinophilic myocarditis; Cardiac MRI: Lake Louise criteria positive (edema on T2 + early gadolinium enhancement + LGE) with subendocardial/endocardial-predominant LGE pattern + eosinophilia → eosinophilic myocarditis.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — Eosinophilic myocarditis (hypersensitivity / parasitic / HES / EGPA)** (cardio.cardiogenic-shock.eosinophilic-myocarditis.v1).
Scope: Confirm eosinophilic myocarditis with cardiogenic shock — peripheral eosinophilia >1500/µL + LV dysfunction + shock physiology + ESC 2013 myocarditis criteria; identify etiology (drug-induced/parasitic/HES/EGPA/idiopathic)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Eosinophilic myocarditis CS — STEROIDS as foundation (after parasite exclusion); etiology-specific add-ons (imatinib for FIP1L1-PDGFRA+ HES; mepolizumab for refractory HES; cyclophosphamide/rituximab for EGPA; antiparasitic for parasitic; drug withdrawal for hypersensitivity); standard CS support per parent**.
1. methylprednisolone 1 g IV daily × 3–5 d (pulse therapy) IV daily × 3–5 d (glucocorticoid_iv_pulse, first line) — AHA 2020 myocarditis statement + Brambatti JACC 2017 — pulse steroids are foundation of therapy; dramatic response in 24–72 h in most cases; MUST exclude strongyloides hyperinfection risk first
2. prednisone 1 mg/kg/d (max 80 mg/d) PO PO daily, taper over 6–12 mo (glucocorticoid_oral, first line) — AHA 2020 myocarditis statement — slow taper over 6–12 mo to prevent recurrence; recurrence rate ~25% with rapid taper
3. imatinib 100–400 mg PO daily PO daily (tyrosine_kinase_inhibitor_pdgfra, comorbidity specific) — Cools NEJM 2003 — dramatic response in FIP1L1-PDGFRA+ clonal HES; can be sole therapy or steroid-sparing; check echo + EF before to monitor for cardiotoxicity
4. mepolizumab 300 mg SC q4wk SC q4wk (anti_il5_monoclonal_antibody, comorbidity specific) — Roufosse NEJM 2008 — anti-IL-5 antibody; steroid-sparing in HES + EGPA; FDA approved for HES (2020) and EGPA (2017)
5. cyclophosphamide 0.5–1 g/m² IV monthly × 3–6 mo IV monthly (alkylating_immunosuppressant, comorbidity specific) — EULAR 2016 EGPA + severe organ involvement — induction therapy; combine with steroids; transition to maintenance with rituximab/azathioprine/mepolizumab
6. rituximab 375 mg/m² IV weekly × 4 (or 1 g IV × 2) IV per induction protocol (anti_cd20_monoclonal_antibody, comorbidity specific) — EULAR 2016 EGPA — alternative or maintenance after cyclophosphamide induction; useful if fertility preservation concern
7. albendazole 400 mg PO BID × 5–14 d (varies by organism) PO BID (antiparasitic_benzimidazole, comorbidity specific) — WHO antiparasitic guidelines; combine with steroids cautiously after parasite treatment initiated to prevent inflammation flare
8. ivermectin 200 µg/kg PO daily × 1–2 d (repeat in 2 wks for strongyloides) PO daily (antiparasitic_avermectin, comorbidity specific) — CDC strongyloidiasis treatment — empiric in high-risk patients before steroids; prevents fatal hyperinfection syndrome
9. norepinephrine 0.05–0.5 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor_alpha, first line) — SOAP-II PMID 20200382 — NE first-line in CS; standard CS support while steroids take effect (24–72 h)
10. warfarin 5 mg daily; INR target 2–3 PO daily × 3 mo (vitamin_k_antagonist, comorbidity specific) — AHA 2022 Class IIa for LV thrombus; eosinophilic myocarditis carries elevated thrombus risk from endocardial damage (Loeffler endocarditis pattern)
11. apixaban 5 mg BID (or 2.5 mg BID per dose-reduction criteria) PO BID × 3 mo for mural thrombus prophylaxis (doac_factor_xa_direct, comorbidity specific) — Off-label-but-rational DOAC alternative for LV thrombus prophylaxis

Setting playbook (outpatient) — Long-term care — 4–8 week recovery echo + 3 mo CMR for endocardial fibrosis screen (Loeffler endocarditis progression); steroid taper continuation; etiology-specific maintenance; ICD evaluation if persistent severe LV dysfunction or refractory VT/VF; recurrence surveillance
12. continue prednisone taper over 6–12 mo taper per schedule PO daily — Maintenance phase (AHA 2020 slow taper to prevent recurrence)
13. continue or de-escalate etiology-specific therapy per response per protocol per protocol — Long-term remission (HES → maintain imatinib/mepolizumab; EGPA → maintenance with rituximab/azathioprine/mepolizumab; parasitic → completed course)
14. discontinue warfarin / apixaban at 3 mo if EF recovered + endocardial damage stable taper / stop PO n/a — Normalized echo + CMR at 3 mo (Mural thrombus risk resolves with disease control)
15. continue HFrEF GDMT if persistent LV dysfunction lisinopril + carvedilol + MRA + SGLT2i per AHA 2022 PO as scheduled — Persistent EF<40 (AHA 2022 HF Class I)

Non-pharmacologic actions:
- ICD evaluation if persistent EF <35 at 90 d (MADIT-II) or recurrent VT/VF
- Cardiac rehab
- Long-term multidisciplinary follow-up per etiology
- Recurrence education — ~25% with rapid taper; adherence critical

AVOID / contraindication checks:
- Steroids_AVOID_until_strongyloides_excluded (steroids cause fatal hyperinfection syndrome in undiagnosed strongyloidiasis; empiric ivermectin if high risk and unable to wait for serology)
- Imatinib_monitor_lvef_at_baseline_and_q3mo (rare cardiotoxicity reported; monitor especially if pre existing LV dysfunction)
- Cyclophosphamide_avoid_if_egfr_lt_30_or_use_dose_reduced (renal clearance significant)
- Cyclophosphamide_pneumocystis_prophylaxis (TMP SMX or atovaquone) (immunosuppression risk)
- Rituximab_screen_for_HBV_HCV (reactivation risk requires antiviral prophylaxis)
- Mepolizumab_pre_treat_for_helminth_infections (anti IL 5 may impair host defense against parasites)
- Steroid_stress_dose_for_acute_illness_during_taper (adrenal suppression risk during long taper)

Monitoring

Regimen monitoring:
- arterial line continuous BP (ACC/AHA 2022 Class I)
- central venous access (ACC/AHA 2022)
- lactate q1-2h (CardShock, Harjola EHJ 2015) — rapid clearance with steroid response
- UOP hourly (SCAI 2019 end-organ perfusion marker)
- DAILY eosinophil count (steroid response marker — should drop within 24–48 h; persistent eosinophilia = steroid failure → escalate to imatinib/mepolizumab)
- serial echo q24-48h for LV recovery trajectory
- telemetry continuous (heart block + arrhythmic surveillance from conduction system infiltrate)
- troponin trend (myocardial injury resolution marker)
- glucose q6h during steroid pulse (hyperglycemia risk)
- k + mg replacement (steroid-induced hypokalemia)

Setting (outpatient) monitoring:
- Quarterly cardiology + etiology specialist visits
- Annual CMR for fibrosis surveillance if Loeffler pattern
- Eosinophil count monthly during taper, then quarterly

Follow-up plan: Repeat echo at 4–8 wks for LV recovery assessment; CMR at 3 mo for endocardial fibrosis screen (Loeffler endocarditis progression); steroid taper over 6–12 mo (slow taper given recurrence risk); long-term mepolizumab/imatinib if HES; rheumatology long-term care if EGPA; ICD evaluation if persistent severe LV dysfunction or refractory VT/VF; recurrence ~25% if rapid steroid taper
- Close-out criterion: Recovery echo + steroid taper plan + etiology-specific long-term plan documented

Monitoring phase: A-line, central line, lactate clearance, urine output, telemetry (heart block + arrhythmic surveillance from conduction system involvement), DAILY EOSINOPHIL COUNT (steroid response marker — should drop within 24–48 h), serial echo q24–48h for LV recovery, troponin trend

Disposition

Current setting: outpatient — Long-term care — 4–8 week recovery echo + 3 mo CMR for endocardial fibrosis screen (Loeffler endocarditis progression); steroid taper continuation; etiology-specific maintenance; ICD evaluation if persistent severe LV dysfunction or refractory VT/VF; recurrence surveillance

Disposition criteria:
- Sustained remission (steroid-free or low-dose maintenance) + EF recovered + no recurrence → annual surveillance with continued etiology specialist follow-up

Escalation triggers (move to higher acuity):
- Recurrence with rising eosinophil count → urgent multidisciplinary reassessment + steroid re-pulse
- Restrictive cardiomyopathy progression → advanced HF eval (transplant candidacy if young)
- Refractory VT/VF → ICD
- Chronic kidney disease from cyclophosphamide → renal protective regimen

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] DRESS syndrome (fever + rash + lymphadenopathy + eosinophilia + multi-organ failure including hepatitis + nephritis) with cardiac involvement — DISCONTINUE offending drug + steroids; high mortality if not recognized
- [LIFE_THREATENING] No clinical response to steroids at 72 h + rising troponin + persistent eosinophilia + echo showing endocardial fibrosis pattern → progression to restrictive cardiomyopathy (Loeffler endocarditis); add second-line therapy + advanced HF evaluation
- [LIFE_THREATENING] Recurrent VT/VF or progressive heart block from eosinophilic infiltration of conduction system despite steroid therapy → temporary pacing → permanent pacemaker if persistent; ICD evaluation for VT/VF

Citations

- ESC 2013 myocarditis position paper (Caforio et al PMID 23824828); AHA 2020 myocarditis scientific statement (Cooper et al); EULAR 2016 EGPA management; Klion 2015 hypereosinophilic syndromes; Brambatti JACC 2017 eosinophilic myocarditis case series [PMID:23824828](https://pubmed.ncbi.nlm.nih.gov/23824828/)
- Cited evidence (PMID 28818220) [PMID:28818220](https://pubmed.ncbi.nlm.nih.gov/28818220/)
- Cited evidence (PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)
- Cited evidence (PMID 20200382) [PMID:20200382](https://pubmed.ncbi.nlm.nih.gov/20200382/)
- Cited evidence (PMID 33704937) [PMID:33704937](https://pubmed.ncbi.nlm.nih.gov/33704937/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ESC 2013 myocarditis position paper (Caforio et al PMID 23824828); AHA 2020 myocarditis scientific statement (Cooper et al); EULAR 2016 EGPA management; Klion 2015 hypereosinophilic syndromes; Brambatti JACC 2017 eosinophilic myocarditis case series — PMID:23824828
  • Cited evidence (PMID 28818220) — PMID:28818220
  • Cited evidence (PMID 35718438) — PMID:35718438
  • Cited evidence (PMID 20200382) — PMID:20200382
  • Cited evidence (PMID 33704937) — PMID:33704937